SG Americas Securities LLC lowered its holdings in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) by 44.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,895 shares of the biotechnology company’s stock after selling 35,344 shares during the quarter. SG Americas Securities LLC owned 0.06% of Coherus BioSciences worth $567,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also bought and sold shares of CHRS. Point72 Hong Kong Ltd bought a new position in Coherus BioSciences during the fourth quarter valued at $119,000. Teacher Retirement System of Texas purchased a new stake in shares of Coherus BioSciences in the fourth quarter valued at $191,000. Inspire Investing LLC purchased a new stake in shares of Coherus BioSciences in the first quarter valued at $234,000. Natixis Advisors L.P. raised its stake in shares of Coherus BioSciences by 13.0% in the fourth quarter. Natixis Advisors L.P. now owns 16,773 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 1,933 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in shares of Coherus BioSciences in the fourth quarter valued at $284,000. Institutional investors own 97.85% of the company’s stock.
Coherus BioSciences Trading Up 0.4 %
NASDAQ CHRS opened at $10.06 on Thursday. The company has a debt-to-equity ratio of 33.47, a quick ratio of 3.09 and a current ratio of 3.33. The company has a market capitalization of $778.88 million, a price-to-earnings ratio of -3.68 and a beta of 1.19. The company’s 50-day simple moving average is $7.68 and its two-hundred day simple moving average is $10.03. Coherus BioSciences, Inc. has a one year low of $5.60 and a one year high of $19.32.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on CHRS shares. Barclays reduced their target price on shares of Coherus BioSciences from $20.00 to $15.00 in a research note on Monday, May 9th. UBS Group started coverage on shares of Coherus BioSciences in a research note on Monday, June 13th. They issued a “neutral” rating and a $7.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Coherus BioSciences in a research note on Tuesday, May 3rd. Finally, Mizuho reduced their price target on shares of Coherus BioSciences from $30.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, May 20th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.00.
Coherus BioSciences Profile
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis.
Read More
- Get a free copy of the StockNews.com research report on Coherus BioSciences (CHRS)
- There Are Different Types of Stock To Invest In
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- Two High-Yield Deep-Values You Shouldn’t Ignore
- PayPal Continues To Struggle As Competition Increases
- Is Starbucks Shooting For The Moon?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
